OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company, announced it will present Phase 2 data for its dry eye disease treatment, OK-101, at the Dry Horizons Symposium. This event is a partner meeting of the Association for Research in Vision and Ophthalmology (ARVO), scheduled for May 3, 2024, in Seattle, WA.
The Markets by Proactive
Go to Proactive UK
Proactive’s coverage of London’s small caps continues on .com